Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Molecular Templates, Inc. | v236238_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 30, 2011
THRESHOLD PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware
|
001-32979
|
94-3409596
|
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
170 Harbor Way, Suite 300
South San Francisco, California 94080
(Address of principal executive offices)(Zip Code)
(650) 474-8200
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On September 30, 2011, Threshold Pharmaceuticals, Inc. issued a press release announcing, in collaboration with Sarcoma Alliance for Research through Collaboration (SARC), the initiation of a Phase 3 randomized clinical trial of TH-302 in combination with doxorubicin, in patients with soft tissue sarcoma. The press release is attached as Exhibit 99.1 to this Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit 99.1 Press release dated September 30, 2011.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
THRESHOLD PHARMACEUTICALS, INC.
|
|||
|
|
By:
|
/s/ Joel A. Fernandes | |
|
Joel A. Fernandes
|
|||
|
Vice President, Finance and Controller
|
|||
Date: September 30, 2011
3
Exhibit Index
| Exhibit No. | Description | |
| Exhibit 99.1 | Press release dated September 30, 2011. |
4